GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Total Long-Term Assets

Estrella Immunopharma (Estrella Immunopharma) Total Long-Term Assets : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Estrella Immunopharma's Total Long-Term Assets for the quarter that ended in Mar. 2024 was $0.00 Mil.


Estrella Immunopharma Total Long-Term Assets Historical Data

The historical data trend for Estrella Immunopharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Total Long-Term Assets Chart

Estrella Immunopharma Annual Data
Trend Jun21
Total Long-Term Assets
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 - - - -

Estrella Immunopharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Estrella Immunopharma Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines